Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
The purpose of this study is to evaluate the safety and efficacy of parsaclisib when combined with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular lymphoma (FL).
Lymphoma
DRUG: Parsaclisib|DRUG: Hexal|DRUG: Gazyvaro
Safety and tolerability of parsaclisib in combination with bendamustine and obinutuzumab in relapsed or refractory FL, assessed by number of subjects with adverse events (AEs), Screening through 30-35 days after end of treatment, up to approximately 34 months per subject
Objective response rate based on Lugano classification criteria, Defined as percentage of subjects with a complete response (CR) and partial response (PR), as determined by investigator assessment of response, Protocol-defined timepoints throughout the treatment period, up to approximately 34 months per subject|Complete response rate based on Lugano classification criteria, Defined as percentage of subjects who achieve a best overall response of CR, Protocol-defined timepoints throughout the treatment period, up to approximately 34 months per subject|Duration of response, Defined as time from first documented evidence of CR or PR until earliest date of disease progression or death due to any cause., Protocol-defined timepoints throughout the treatment period, up to approximately 34 months per subject|Progression-free survival, Defined as time from the date of the first dose of study drug until the earliest date of disease progression (determined by radiographic disease assessment/Lugano classification criteria) or death due to any cause., Protocol-defined timepoints throughout the treatment period, up to approximately 34 months per subject|Overall survival, Defined as the time from the date of the first dose of study drug until death due to any cause., From the date of the first dose of study drug until death due to any cause, assessed up to approximately 34 months per subject
The purpose of this study is to evaluate the safety and efficacy of parsaclisib when combined with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular lymphoma (FL).